RxDoctor Payments Data

Jayadeva Chowdappa, MD

Internal Medicine · Trinity, FLNPI 1609871805

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Conmed Corporation at 27.8% of the total. Reporting peaked in 2020 at $75 and has fallen 73.1% since, to $20 in 2025. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.

$233in general payments, 2019–2025

Across 13 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Conmed Corporation$65
  • AstraZeneca$62
  • Johnson & Johnson$40
  • Amgen$20
  • Lilly USA, LLC$20
  • Amarin Pharma, Inc.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$22195%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$233 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$41,831
Medicare patients
109
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$84,703
BiktarvyBictegrav/Emtricit/Tenofov Ala13$52,024
XareltoRivaroxaban36$35,094
FarxigaDapagliflozin Propanediol30$24,077
SymbicortBudesonide/Formoterol Fumarate56$18,923
EntrestoSacubitril/Valsartan11$12,553
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,009
Breo ElliptaFluticasone/Vilanterol18$7,692
TradjentaLinagliptin13$6,692
Tresiba Flextouch U-100Insulin Degludec13$6,230
Atorvastatin Calcium712$5,463
Albuterol Sulfate HfaAlbuterol Sulfate139$4,884
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm39$4,664
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$4,566
Levothyroxine Sodium417$4,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$62$43,00086 claims
Johnson & JohnsonXarelto$40$35,09436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →